Last reviewed 2026-04-20 · How we verify

Bisulepin (bisulepine)

Bisulepin (generic name: bisulepine) is a drug. It is currently in unknown development.

Bisulepin works by binding to the histamine H1 receptor, which is involved in regulating various physiological processes, including sleep, appetite, and immune responses.

Bisulepin (bisulepine) is a small molecule modality targeting the histamine H1 receptor. Its exact drug class is unknown, and its commercial status is unclear. Bisulepin is not FDA-approved for any indications, and its pharmacokinetic properties, such as half-life and bioavailability, are also unknown. As a result, there is limited information available on its safety profile and potential side effects. Further research is needed to fully understand the properties and potential uses of bisulepin.

At a glance

Mechanism of action

Think of histamine like a messenger in your body that helps control things like sleep, appetite, and how your body reacts to allergens. Bisulepin blocks this messenger from doing its job, which can help with certain conditions. However, this can also have unintended effects, so it's essential to understand how bisulepin interacts with the body before using it.

Approved indications

No approved indications tracked.

Common side effects

• Cytokine release syndrome
• COVID-19 pneumonia
• Haemolytic uraemic syndrome
• Oligohydramnios

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Bisulepin CI brief — competitive landscape report
• Bisulepin updates RSS · CI watch RSS
• portfolio CI

Frequently asked questions about Bisulepin

Related

• Target: All drugs targeting Histamine H1 receptor
• Manufacturer: — full pipeline
• Therapeutic area: All drugs in Immunology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing